8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Mar 5, 2026·SEC
Material company update
Nov 17, 2025·SEC
Bioventus Inc.(BVS)Earnings, Financials & Key Ratios
BVS•NASDAQ
25.8× P/E·Price updated May 30, 2026
AboutBioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.Show more
- Revenue$568M-0.9%
- EBITDA$106M+180.9%
- Net Income$23M+167.8%
- EPS (Diluted)0.33+163.5%
- Gross Margin67.32%-0.6%
- EBITDA Margin18.58%+183.5%
- Operating Margin10.31%+593.2%
- Net Margin4%+168.4%
- ROE10.98%+166.6%
- ROIC9.07%+634.4%
- Debt/Equity1.36-24.6%
- Interest Coverage2.21+929.8%
BVS Key Insights
Bioventus Inc. (BVS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong Piotroski F-Score: 7/9
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 12.1%
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when BVS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BVS Price & Volume
Bioventus Inc. (BVS) stock price & volume — 10-year historical chart
Loading chart...
BVS Growth Metrics
Bioventus Inc. (BVS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years12.08%
3 Years3.52%
TTM1.52%
Profit CAGR
10 Years-
5 Years6.73%
3 Years-
TTM185.53%
EPS CAGR
10 Years-
5 Years-5.59%
3 Years-
TTM185.12%
Return on Capital
10 Years0.16%
5 Years-2.91%
3 Years-0.14%
Last Year11.25%
BVS Recent Earnings
Bioventus Inc. (BVS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 6, 2026EPS
$0.15
Est $0.09
+66.7%
Revenue
$132M
Est $130M
+1.7%
Q2 2026
Mar 5, 2026EPS
$0.24
Est $0.22
+9.1%
Revenue
$158M
Est $155M
+1.9%
Q4 2025
Nov 4, 2025EPS
$0.15
Est $0.21
-30.2%
Revenue
$139M
Est $156M
-11.0%
Q3 2025
Aug 6, 2025EPS
$0.21
Est $0.22
-4.5%
Revenue
$148M
Est $139M
+6.4%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.15vs $0.09+66.7% | $132Mvs $130M+1.7% |
| Q2 2026 | Mar 5, 2026 | $0.24vs $0.22+9.1% | $158Mvs $155M+1.9% |
| Q4 2025 | Nov 4, 2025 | $0.15vs $0.21-30.2% | $139Mvs $156M-11.0% |
| Q3 2025 | Aug 6, 2025 | $0.21vs $0.22-4.5% | $148Mvs $139M+6.4% |
Based on last 12 quarters of dataView full earnings history →
BVS Peer Comparison
Bioventus Inc. (BVS) competitors in Orthopedics, spine, and sports medicine — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NVCR | 1.94B | 17.04 | -13.97 | 8.28% | -25.66% | -50.82% | 0.85 | |
 OSUR | 309.45M | 4.30 | -4.57 | -38.1% | -61.93% | -15.09% | 0.04 | |
 ATRC | 1.4B | 27.67 | -115.29 | 14.88% | -0.83% | -0.95% | 0.18 | |
 LNTH | 6.47B | 99.30 | 29.12 | 0.5% | 18.05% | 24.33% | 0.00 | |
 MASI | 9.34B | 178.45 | -63.73 | -27.1% | 4.9% | 9.08% | 0.78 | |
 ANGO | 477.27M | 11.48 | -13.83 | -3.76% | -9.02% | -15.71% | ||
 GMED | 11.04B | 81.88 | 20.89 | 16.65% | 18.92% | 13.04% | 0.03 | |
 OFIX | 374.71M | 9.27 | -4.07 | 2.85% | -7.27% | -13.44% | 0.51 |
Compare BVS vs Peers
Bioventus Inc. (BVS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BVS Income Statement
Bioventus Inc. (BVS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'15 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 253.65M | 319.18M | 340.14M | 321.16M | 430.9M | 512.12M | 512.35M | 573.28M | 568.09M | 576.3M |
Revenue Growth % | 4.43% | 25.83% | 6.57% | -5.58% | 34.17% | 18.85% | 0.04% | 11.89% | -0.91% | 1.52% |
Cost of Goods Sold | 74.34M | 84.17M | 90.94M | 87.64M | 128.19M | 181.04M | 184.15M | 185.05M | 185.66M | 186.16M |
COGS % of Revenue | 29.31% | 26.37% | 26.73% | 27.29% | 29.75% | 35.35% | 35.94% | 32.28% | 32.68% | - |
Gross Profit | 179.31M▲ 0% | 235.01M▲ 31.1% | 249.21M▲ 6.0% | 233.52M▼ 6.3% | 302.71M▲ 29.6% | 331.08M▲ 9.4% | 328.19M▼ 0.9% | 388.23M▲ 18.3% | 382.43M▼ 1.5% | 390.14M▲ 0% |
Gross Margin % | 70.69% | 73.63% | 73.27% | 72.71% | 70.25% | 64.65% | 64.06% | 67.72% | 67.32% | 67.7% |
Gross Profit Growth % | 6.55% | 31.06% | 6.04% | -6.29% | 29.63% | 9.37% | -0.87% | 18.29% | -1.49% | - |
Operating Expenses | 173.76M | 209.5M | 218.01M | 212.28M | 290.64M | 498.31M | 409.92M | 400.2M | 323.88M | 331M |
OpEx % of Revenue | 68.5% | 65.64% | 64.09% | 66.1% | 67.45% | 97.3% | 80.01% | 69.81% | 57.01% | - |
Selling, General & Admin | 148.44M | 191.67M | 198.47M | 193.08M | 254.25M | 332.13M | 303.88M | 327.09M | 314.03M | 318M |
SG&A % of Revenue | 58.52% | 60.05% | 58.35% | 60.12% | 59.01% | 64.86% | 59.31% | 57.06% | 55.28% | - |
Research & Development | 14.75M | 8.1M | 11.05M | 11.2M | 19.04M | 23.85M | 13.45M | 13.64M | 12.11M | 11.57M |
R&D % of Revenue | 5.81% | 2.54% | 3.25% | 3.49% | 4.42% | 4.66% | 2.62% | 2.38% | 2.13% | - |
Other Operating Expenses | 10.57M | 9.74M | 8.48M | 8M | 17.35M | 142.33M | 92.59M | 59.47M | -2.26M | 1000K |
Operating Income | -16.59M▲ 0% | 25.5M▲ 253.7% | 31.19M▲ 22.3% | 21.24M▼ 31.9% | 12.06M▼ 43.2% | -167.23M▼ 1486.6% | -81.72M▲ 51.1% | -11.98M▲ 85.3% | 58.55M▲ 588.7% | 61.08M▲ 0% |
Operating Margin % | -6.54% | 7.99% | 9.17% | 6.61% | 2.8% | -32.66% | -15.95% | -2.09% | 10.31% | 10.6% |
Operating Income Growth % | -83040% | 253.75% | 22.31% | -31.92% | -43.21% | -1486.57% | 51.13% | 85.34% | 588.75% | - |
EBITDA | 16.49M | 54.74M | 61.51M | 49.88M | 46.94M | -111.84M | -24.36M | 37.58M | 105.56M | 107.43M |
EBITDA Margin % | 6.5% | 17.15% | 18.08% | 15.53% | 10.89% | -21.84% | -4.75% | 6.55% | 18.58% | 18.64% |
EBITDA Growth % | -42.82% | 231.97% | 12.36% | -18.91% | -5.9% | -338.27% | 78.22% | 254.25% | 180.92% | 206.14% |
D&A (Non-Cash Add-back) | 33.08M | 29.24M | 30.32M | 28.64M | 34.88M | 55.4M | 57.37M | 49.55M | 47.01M | 46.35M |
EBIT | -17.74M | 25.28M | 31.27M | 25.66M | 10.6M | -177M | -80.44M | -10.33M | 58.55M | 63.34M |
Net Interest Income | -14.23M | -19.17M | -21.58M | -9.75M | -1.11M | -12.02M | -40.68M | -38.79M | -26.49M | -23.3M |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 14.23M | 19.17M | 21.58M | 9.75M | 1.11M | 12.02M | 40.68M | 38.79M | 26.49M | 23.3M |
Other Income/Expense | -15.38M | -19.4M | -21.5M | -5.32M | -2.57M | -21.79M | -39.39M | -37.15M | -32.84M | -27.44M |
Pretax Income | -31.97M▲ 0% | 6.11M▲ 119.1% | 9.69M▲ 58.7% | 15.91M▲ 64.2% | 9.49M▼ 40.4% | -189.03M▼ 2092.3% | -121.11M▲ 35.9% | -49.13M▲ 59.4% | 25.71M▲ 152.3% | 33.64M▲ 0% |
Pretax Margin % | -12.6% | 1.91% | 2.85% | 4.96% | 2.2% | -36.91% | -23.64% | -8.57% | 4.53% | 5.84% |
Income Tax | 2.14M | 1.66M | 1.58M | 1.19M | -1.97M | -44.37M | 85K | -5.29M | -1.56M | -899K |
Effective Tax Rate % | -6.69% | 27.25% | 16.27% | 7.49% | -20.72% | 23.48% | -0.07% | 10.77% | -6.09% | -2.67% |
Net Income | -34.11M▲ 0% | -12.21M▲ 64.2% | 6.85M▲ 156.1% | 16.41M▲ 139.5% | 19.38M▲ 18.1% | -158.7M▼ 919.1% | -156.23M▲ 1.6% | -33.54M▲ 78.5% | 22.73M▲ 167.8% | 28.48M▲ 0% |
Net Margin % | -13.45% | -3.82% | 2.01% | 5.11% | 4.5% | -30.99% | -30.49% | -5.85% | 4% | 4.94% |
Net Income Growth % | -164.43% | 64.21% | 156.12% | 139.54% | 18.06% | -919.12% | 1.56% | 78.53% | 167.77% | 185.53% |
Net Income (Continuing) | -34.11M | 4.44M | 8.11M | 14.72M | 11.45M | -144.65M | -121.2M | -43.83M | 27.27M | 34.54M |
Discontinued Operations | 0 | 0 | 0 | 0 | -1.87M | -54.78M | -59.49M | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 2.63M | 1.92M | 74.86M | 86.98M | 47.53M | 37.66M | 44.34M | 45.36M |
EPS (Diluted) | -0.69▲ 0% | -0.22▲ 68.1% | 0.12▲ 154.5% | 0.44▲ 266.7% | -0.15▼ 134.1% | -2.59▼ 1626.7% | -2.49▲ 3.9% | -0.52▲ 79.1% | 0.33▲ 163.5% | 0.41▲ 0% |
EPS Growth % | -130% | 68.12% | 154.55% | 266.67% | -134.09% | -1626.67% | 3.86% | 79.12% | 163.46% | 185.12% |
EPS (Basic) | -0.69 | -0.22 | 0.12 | 0.44 | -0.15 | -2.59 | -2.49 | -0.52 | 0.34 | - |
Diluted Shares Outstanding | 55.63M | 56.83M | 56.83M | 37.7M | 45.47M | 61.39M | 62.65M | 65.36M | 68.91M | 70.01M |
Basic Shares Outstanding | 55.63M | 56.83M | 56.83M | 37.7M | 45.47M | 61.39M | 62.65M | 65.36M | 66.62M | 67.3M |
Dividend Payout Ratio | - | - | 133.37% | 121.17% | 1.89% | - | - | - | - | - |
BVS Balance Sheet
Bioventus Inc. (BVS) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'15 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 99.43M | 148.35M | 183.03M | 211.79M | 263.1M | 272.57M | 268M | 275.61M | 272.84M | 249.81M |
Cash & Short-Term Investments | 4.95M | 42.77M | 64.52M | 86.84M | 43.93M | 30.19M | 36.96M | 41.58M | 51.24M | 35.85M |
Cash Only | 4.95M | 42.77M | 64.52M | 86.84M | 43.93M | 30.19M | 36.96M | 41.58M | 51.24M | 35.85M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 54.51M | 73.04M | 85.13M | 88.28M | 124.96M | 136.29M | 122.79M | 127.39M | 128.3M | 120.53M |
Days Sales Outstanding | 78.44 | 83.53 | 91.35 | 100.33 | 105.85 | 97.14 | 87.48 | 81.11 | 82.44 | 81.01 |
Inventory | 35.18M | 27.4M | 27.33M | 29.12M | 61.69M | 84.77M | 91.33M | 92.47M | 82.24M | 83.19M |
Days Inventory Outstanding | 172.71 | 118.8 | 109.68 | 121.28 | 175.64 | 170.9 | 181.03 | 182.4 | 161.68 | 175.56 |
Other Current Assets | 343K | 224K | 0 | 0 | 20.28M | 16.89M | 16.91M | 14.16M | 11.06M | 10.26M |
Total Non-Current Assets | 387.93M | 294.37M | 289.37M | 282.67M | 962.76M | 1.1B | 542.91M | 452.35M | 410.72M | 400.73M |
Property, Plant & Equipment | 9.6M | 4.76M | 19.76M | 21.84M | 40.17M | 44.15M | 49.96M | 33.52M | 27.02M | 25.98M |
Fixed Asset Turnover | 26.42x | 67.07x | 17.22x | 14.71x | 10.73x | 11.60x | 10.26x | 17.10x | 21.02x | 20.48x |
Goodwill | 58.69M | 49.8M | 49.8M | 49.8M | 147.62M | 7.46M | 7.46M | 7.46M | 7.46M | 7.46M |
Intangible Assets | 319.15M | 237.03M | 216.51M | 191.65M | 695.19M | 639.85M | 482.35M | 404.73M | 368.42M | 359.66M |
Long-Term Investments | 0 | 2.78M | 3.31M | 19.38M | 29.29M | 2.64M | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 393K | 0 | 0 | 0 | 50M | 405.98M | 3.14M | 1.89M | 2.29M | 2.1M |
Total Assets | 487.35M▲ 0% | 442.72M▼ 9.2% | 472.41M▲ 6.7% | 494.47M▲ 4.7% | 1.23B▲ 147.9% | 1.37B▲ 12.0% | 810.91M▼ 40.9% | 727.96M▼ 10.2% | 683.56M▼ 6.1% | 650.54M▲ 0% |
Asset Turnover | 0.52x | 0.72x | 0.72x | 0.65x | 0.35x | 0.37x | 0.63x | 0.79x | 0.83x | 0.84x |
Asset Growth % | 13.23% | -9.16% | 6.7% | 4.67% | 147.92% | 11.97% | -40.92% | -10.23% | -6.1% | -31.61% |
Total Current Liabilities | 87.69M | 65.43M | 89.02M | 122.59M | 180.86M | 304.02M | 175.5M | 210.4M | 160.38M | 148.09M |
Accounts Payable | 8.37M | 8.21M | 6.44M | 4.42M | 16.91M | 36.7M | 23.04M | 23.69M | 10.93M | 24.05M |
Days Payables Outstanding | 41.08 | 35.59 | 25.85 | 18.42 | 48.16 | 73.99 | 45.66 | 46.73 | 21.48 | 42.09 |
Short-Term Debt | 36.48M | 5.25M | 10M | 15M | 18.04M | 33.06M | 27.85M | 27.34M | 19.21M | 18.75M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 26.77M | 25.73M | 22.98M | 20.86M | 46.48M | 151.07M | 34.23M | 51.13M | 125.11M | 105.3M |
Current Ratio | 1.13x | 2.27x | 2.06x | 1.73x | 1.45x | 0.90x | 1.53x | 1.31x | 1.70x | 1.70x |
Quick Ratio | 0.73x | 1.85x | 1.75x | 1.49x | 1.11x | 0.62x | 1.01x | 0.87x | 1.19x | 1.19x |
Cash Conversion Cycle | 210.07 | 166.74 | 175.18 | 203.19 | 233.33 | 194.06 | 222.84 | 216.78 | 222.63 | 214.48 |
Total Non-Current Liabilities | 207.32M | 232.03M | 237.78M | 227.72M | 511.21M | 656.41M | 414.3M | 331.95M | 294.73M | 268.18M |
Long-Term Debt | 157.61M | 189.58M | 187.97M | 173.38M | 339.64M | 385.01M | 367M | 308.29M | 278.95M | 0 |
Capital Lease Obligations | 1.22M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13.19M | 13.19M |
Deferred Tax Liabilities | 8.78M | 3.96M | 3.87M | 3.36M | 133.52M | 2.25M | 1.21M | 564K | 433K | 2.44M |
Other Non-Current Liabilities | 39.72M | 38.49M | 45.94M | 50.98M | 38.05M | 269.15M | 46.08M | 23.1M | 2.16M | 267.61M |
Total Liabilities | 295.01M | 297.46M | 326.79M | 350.31M | 692.07M | 960.43M | 589.79M | 542.35M | 455.11M | 416.27M |
Total Debt | 196.51M | 194.83M | 197.97M | 188.38M | 357.68M | 418.07M | 394.85M | 335.63M | 311.35M | 18.75M |
Net Debt | 191.56M | 152.05M | 133.44M | 101.54M | 313.75M | 387.88M | 357.88M | 294.05M | 260.11M | -17.1M |
Debt / Equity | 1.02x | 1.34x | 1.36x | 1.31x | 0.67x | 1.01x | 1.79x | 1.81x | 1.36x | 1.36x |
Debt / EBITDA | 11.92x | 3.56x | 3.22x | 3.78x | 7.62x | - | - | 8.93x | 2.95x | 0.17x |
Net Debt / EBITDA | 11.62x | 2.78x | 2.17x | 2.04x | 6.68x | - | - | 7.83x | 2.46x | 2.46x |
Interest Coverage | -1.25x | 1.32x | 1.45x | 2.63x | 9.53x | -14.72x | -1.98x | -0.27x | 2.21x | 2.72x |
Total Equity | 192.34M▲ 0% | 145.27M▼ 24.5% | 145.62M▲ 0.2% | 144.16M▼ 1.0% | 533.79M▲ 270.3% | 412.22M▼ 22.8% | 221.12M▼ 46.4% | 185.6M▼ 16.1% | 228.45M▲ 23.1% | 234.26M▲ 0% |
Equity Growth % | 8.37% | -24.47% | 0.24% | -1% | 270.28% | -22.77% | -46.36% | -16.06% | 23.08% | 66.79% |
Book Value per Share | 3.46 | 2.56 | 2.56 | 3.82 | 11.74 | 6.71 | 3.53 | 2.84 | 3.31 | 3.35 |
Total Shareholders' Equity | 192.34M | 145.27M | 142.98M | 142.24M | 458.92M | 325.24M | 173.59M | 147.94M | 184.1M | 188.9M |
Common Stock | 113.37M | 285.15M | 285.15M | 285.17M | 75K | 78K | 79K | 82K | 83K | 84K |
Retained Earnings | -91.84M | -139.82M | -141.7M | -144.54M | -6.6M | -165.31M | -321.54M | -355.08M | -334.93M | -331.82M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -650K | -65K | -465K | 1.61M | 179K | -110K | 794K | -2.57M | -1.9M | -2.28M |
Minority Interest | 0 | 0 | 2.63M | 1.92M | 74.86M | 86.98M | 47.53M | 37.66M | 44.34M | 45.36M |
BVS Cash Flow Statement
Bioventus Inc. (BVS) cash flow — operating, investing & free cash flow history
| Metric | Dec'15 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 18.92M | 45.19M | 40.71M | 71.8M | 22.99M | -13.54M | 15.34M | 38.8M | 73.98M | 73.98M |
Operating CF Margin % | 7.46% | 14.16% | 11.97% | 22.36% | 5.34% | -2.64% | 2.99% | 6.77% | 13.02% | - |
Operating CF Growth % | 25.22% | 138.83% | -9.9% | 76.35% | -67.98% | -158.88% | 213.35% | 152.84% | 90.68% | 505.55% |
Net Income | -34.11M | 4.44M | 8.11M | 14.72M | 11.45M | -144.65M | -121.2M | -318K | 0 | 28.48M |
Depreciation & Amortization | 33.08M | 29.24M | 30.32M | 28.64M | 34.88M | 55.4M | 57.37M | 49.55M | 0 | 46.35M |
Stock-Based Compensation | 0 | 14.32M | 0 | 10.1M | 19.84M | 17.59M | 2.72M | 10.06M | 0 | 7.08M |
Deferred Taxes | -432K | -79K | -348K | 0 | -9.76M | -46.66M | -2.38M | -5.39M | 0 | -817K |
Other Non-Cash Items | 31.03M | -5.59M | 16.2M | 3.02M | -18.28M | 134.52M | 82.01M | -3.33M | 87.82M | 10.28M |
Working Capital Changes | -10.65M | 2.85M | -13.57M | 15.31M | -15.14M | -29.73M | -3.18M | -11.78M | -13.84M | 7.19M |
Change in Receivables | -11.27M | -12.13M | -14.91M | 0 | -20.05M | -17.67M | 10.05M | -10.67M | -916K | -2.6M |
Change in Inventory | -5.73M | 3.26M | -1.43M | 0 | 3.18M | -18.62M | 0 | -16.43M | 8.57M | 7.8M |
Change in Payables | 5.18M | 12.15M | 6.65M | 0 | 0 | 0 | 0 | 0 | -19.81M | -8.06M |
Cash from Investing | -60.19M | -6.1M | -7.91M | -20.5M | -283.76M | -116.44M | 15.81M | 22.96M | -3.25M | -3M |
Capital Expenditures | -2.12M | -6.06M | -2.34M | -16.58M | -13.52M | -1.48M | -7.36M | -1.01M | 0 | -2.31M |
CapEx % of Revenue | 0.83% | 1.9% | 0.69% | 5.16% | 3.14% | 0.29% | 1.44% | 0.18% | 0.45% | - |
Acquisitions | -51.46M | 0 | 430K | 0 | -262.87M | 0 | 34.67M | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -6.61M | -40K | -6.43M | -3.92M | -7.37M | -114.96M | -11.51M | 23.97M | -3.25M | -686K |
Cash from Financing | 31.25M | -13.26M | -10.95M | -29.57M | 273.37M | 62.08M | -26.65M | -54.58M | -61.44M | -86.23M |
Debt Issued (Net) | -675K | -5.25M | -1.37M | -10M | 166.2M | 59.62M | -23.26M | -59.58M | -42.91M | -75.61M |
Equity Issued (Net) | 0 | 0 | 0 | 0 | 109.41M | 5.82M | 778K | 2.44M | 2.07M | 2.04M |
Dividends Paid | -1.02M | -7.85M | -9.14M | -19.89M | -367K | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 32.94M | -160K | -448K | 317K | -1.88M | -3.37M | -4.17M | 2.56M | -20.61M | -12.67M |
Net Change in Cash | -10.82M▲ 0% | 25.67M▲ 337.2% | 21.75M▼ 15.3% | 22.32M▲ 2.6% | 12.37M▼ 44.6% | -67.38M▼ 644.5% | 5.13M▲ 107.6% | 4.62M▼ 9.9% | 9.66M▲ 109.1% | 13.04M▲ 0% |
Free Cash Flow | 11.48M▲ 0% | 39.13M▲ 240.9% | 32.37M▼ 17.3% | 51.13M▲ 57.9% | 2.1M▼ 95.9% | -15.02M▼ 814.7% | 7.98M▲ 153.2% | 37.79M▲ 373.4% | 71.41M▲ 89.0% | 100.63M▲ 0% |
FCF Margin % | 4.53% | 12.26% | 9.52% | 15.92% | 0.49% | -2.93% | 1.56% | 6.59% | 12.57% | 17.46% |
FCF Growth % | 300.63% | 240.88% | -17.26% | 57.94% | -95.89% | -814.66% | 153.16% | 373.43% | 88.98% | 320.55% |
FCF per Share | 0.21 | 0.69 | 0.57 | 1.36 | 0.05 | -0.24 | 0.13 | 0.58 | 1.04 | 1.04 |
FCF Conversion (FCF/Net Income) | -0.55x | -3.70x | 5.94x | 4.38x | 1.19x | 0.09x | -0.10x | -1.16x | 3.25x | 3.53x |
Interest Paid | 15.63M | 17.27M | 15.45M | 7.49M | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 2.61M | 1.94M | 1.58M | 1.54M | 0 | 0 | 0 | 0 | 0 | 0 |
BVS Key Ratios
Bioventus Inc. (BVS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2015 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -18.45% | -7.23% | 4.71% | 11.33% | 5.72% | -33.55% | -49.34% | -16.49% | 10.98% | 13.08% |
| Return on Invested Capital (ROIC) | -3.47% | 5.62% | 8.12% | 6.07% | 1.65% | -15.22% | -8.89% | -1.7% | 9.07% | 9.07% |
| Gross Margin | 70.69% | 73.63% | 73.27% | 72.71% | 70.25% | 64.65% | 64.06% | 67.72% | 67.32% | 67.7% |
| Net Margin | -13.45% | -3.82% | 2.01% | 5.11% | 4.5% | -30.99% | -30.49% | -5.85% | 4% | 4.94% |
| Debt / Equity | 1.02x | 1.34x | 1.36x | 1.31x | 0.67x | 1.01x | 1.79x | 1.81x | 1.36x | 1.36x |
| Interest Coverage | -1.25x | 1.32x | 1.45x | 2.63x | 9.53x | -14.72x | -1.98x | -0.27x | 2.21x | 2.72x |
| FCF Conversion | -0.55x | -3.70x | 5.94x | 4.38x | 1.19x | 0.09x | -0.10x | -1.16x | 3.25x | 3.53x |
| Revenue Growth | 4.43% | 25.83% | 6.57% | -5.58% | 34.17% | 18.85% | 0.04% | 11.89% | -0.91% | 1.52% |
Related:BVS Dividend History·BVS Revenue History·BVS Price History·BVS P/E History·BVS Financial Ratios·BVS Institutional Holders
BVS SEC Filings & Documents
Bioventus Inc. (BVS) SEC filings — annual & quarterly reports (10-K, 10-Q)
BVS Frequently Asked Questions
Bioventus Inc. (BVS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Bioventus Inc. (BVS) reported $576.3M in revenue for fiscal year 2025. This represents a 137% increase from $242.9M in 2014.
Bioventus Inc. (BVS) saw revenue decline by 0.9% over the past year.
Yes, Bioventus Inc. (BVS) is profitable, generating $28.5M in net income for fiscal year 2025 (4.0% net margin).
Dividend & Returns
Bioventus Inc. (BVS) has a return on equity (ROE) of 11.0%. This is reasonable for most industries.
Bioventus Inc. (BVS) generated $100.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.